Navigation Links
China Shenghuo Pharmaceutical Holdings, Inc. Schedules Conference Call to Discuss FY 2007 Results
Date:3/31/2008

KUNMING, China, March 31 /Xinhua-PRNewswire-FirstCall/ -- China Shenghuo Pharmaceutical Holdings, Inc. (Amex: KUN) ("China Shenghuo" or "the Company"), which is engaged in the research, development, manufacture, and marketing of pharmaceutical, nutritional supplement and cosmetic products in the People's Republic of China ("PRC"), today announced it will conduct a conference call at 8:00 a.m. EDT on Wednesday, April 2, 2008, to discuss the Company's financial results for the fiscal year ended December 31, 2007.

Hosting the call will be Mr. Feng Lan, President, and Ms. Qionghua Gao, Chief Financial Officer.

To participate in the event by telephone, please dial (800) 638-4930 five to 10 minutes prior to the start time (to allow time for registration) and reference the conference ID 28825392. International callers should dial (617) 614-3944 and reference the same passcode.

A digital replay of the call will be available on Wednesday, April 2 at approximately 10:00 a.m. EDT through Wednesday, April 9 at 12 p.m. EDT. To listen to the replay, dial (888) 286-8010 and enter the conference ID number 63812946. International callers should dial (617) 801-6888 and enter the same conference ID number.

The conference call will also be webcast live over the Internet and can be accessed by all interested parties at the company's Web site: http://www.shenghuo.com.cn.

To monitor the live webcast, please visit the Company's Web site and click on the webcast link at least 15 minutes prior to the start of the call to register, download, and install any necessary audio software. An audio replay of the event will be archived on China Shenghuo's Web site.

About China Shenghuo Pharmaceutical Holdings, Inc.

Founded in 1995, China Shenghuo Pharmaceutical Holdings, Inc. ("China Shenghuo" or "the "Company") is a specialty pharmaceutical company that focuses on the research, development, production and marketing of Sanchi-based medicinal products. Through its subsidiary, Kunming Shenghuo Pharmaceutical (Group) Co., Ltd. ("Kunming Shenghuo"), it owns thirty-one SFDA (State Food and Drug Association)-approved medicines, including the flagship product Xuesaitong Soft Capsules, which has already been listed in the Insurance Catalogue. At present, China Shenghuo incorporates a sales network of agencies and representatives throughout China, which markets Sanchi-based traditional Chinese medicine to hospitals and drug stores as prescription and OTC drugs primarily for the treatment of cardiovascular, cerebrovascular and peptic ulcer disease. The Company also exports medicinal products to Asian countries such as Indonesia, Russia and Kyrgyzstan. For more information, please visit http://www.shenghuo.com.cn

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995: This press release contains certain "forward-looking statements," as defined in the United States Private Securities Litigation Reform Act of 1995, that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. Such factors include, but are not limited to, the company's reliance on one supplier for Sanchi, ability to develop and market new products, ability to establish and maintain a strong brand, continued maintenance of certificates, permits and licenses required to conduct business in China, protection of company's intellectual property rights, market acceptance of the company's products, changes in the laws of the People's Republic of China that affect the company's operations, the company's ability to obtain all necessary government certifications and/or licenses to open and operate retail specialty counters to offer its cosmetic products and conduct the company's business, cost of complying with current and future governmental regulations and the impact of any changes in the regulations on the company's operations and other factors detailed from time to time in the Company's filings with the United States Securities and Exchange Commission and other regulatory authorities. The company undertakes no obligation to publicly update or revise any forward- looking statements, whether as a result of new information, future events or otherwise.

For more information, please contact:

China Shenghuo Pharmaceutical Holdings, Inc

Ms. Gao Qionghua, CFO

Tel: +86-871-7282608

Email: qionghua_kmsh@163.com

CCG Elite Investor Relations

Crocker Coulson, President

Tel: +1-646-213-1915 (New York)

Email: crocker.coulson@ccgir.com


'/>"/>
SOURCE China Shenghuo Pharmaceutical Holdings, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. China Medicine Corporation to Present at Brean Murray Carret & Co. Mainland China Investor Tour
2. China Yingxia International, Inc. Announces Record Fourth Quarter and Year 2007 Results
3. China Yingxia International Announces Soybean Milk Production Lines Acquisition
4. Cells from the Research Institute of the MUHC on the road to China
5. China Medicine Announces Record Fourth Quarter and Fiscal Year 2007 Results
6. China Yingxia International Announces 2007 Fourth Quarter and Full Year Financial Results Conference Call
7. China Medicine Announces Conference Call to Discuss Fourth Quarter and Fiscal Year 2007 Results
8. China RuiTai International Holdings Retains CCG Elite for Investor Relations Services
9. China Medical Technologies Receives CE Mark for Two ECLIA Analyzers and 15 Reagents
10. Sinovac to Present at the Brean Murray, Carret & Co. Fourth Investor Tour of China
11. China Nepstar Chain Drugstore Announces Dividend
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2017)... SANTA CLARA, CA (PRWEB) , ... July 24, 2017 , ... ... government and financial organizations, today announced it has partnered with WALLIX to ... NIST Special Publication 800-171 . , There are a number of ways to address ...
(Date:7/24/2017)... ... July 24, 2017 , ... Anyone who uses scales know they ... would a pharmacist using that same scale to dispense medication. The first example is ... These illustrations show why it is important to have the right balance for the ...
(Date:7/24/2017)... ... 24, 2017 , ... A Southern California-based author has released a new book ... she has overcome them. “Forbidden Memories: A Memoir,” by author Michelle V. Madsen, highlights ... risen above. , In “Memories,” readers get a firsthand look at what Michelle has ...
(Date:7/24/2017)... (PRWEB) , ... July 24, 2017 , ... ... how to change manufacturers future. , The agency is hammering out a game ... one of the farthest-ranging laws ever to affect FDA-regulated firms. The new law:, ...
(Date:7/24/2017)... ... 24, 2017 , ... “A Short Walk to the Mailbox”: a remarkable memoir ... of published author, Ed Clark. Ed Clark is a church music director and ... a minister of music and worship leader for over fifty years. He has ...
Breaking Medicine News(10 mins):
(Date:7/10/2017)... S.C. , July 10, 2017  BDI ... purchasing and patient support services organization serving specialty ... today the launch of four significant, value-added member ... market insights, better manage reimbursement and improve access ... and factor therapies. ...
(Date:7/5/2017)... 5, 2017 Oramed Pharmaceuticals Inc. ... ), a clinical-stage pharmaceutical company focused on the development ... received approval from the Israel Securities Authority to dual-list its ... common stock will commence trading on the TASE on July ... market capitalization of the Company, it is expected that Oramed ...
(Date:6/30/2017)... -- AVACEN Medical (AVACEN) announced the publication of new research in the ... its AVACEN Treatment Method to significantly reduce the widespread ... ... ... approximately 200 to 400 million people worldwide according to The National ...
Breaking Medicine Technology: